Weinbrenner Tanja, Cladellas Mercedes, Isabel Covas Maria, Fitó Montserrat, Tomás Marta, Sentí Mariano, Bruguera Jordi, Marrugat Jaume
Unitat de Lípids i Epidemiologia Cardiovascular, Institut d'Investigació Mèdica, Dr Aiguader 80, E-08003, Barcelona, Spain.
Atherosclerosis. 2003 May;168(1):99-106. doi: 10.1016/s0021-9150(03)00053-4.
Oxidized low density lipoprotein (oxLDL) plays a pivotal role in the development of atherosclerosis. The aim of the study was to investigate the relationship between oxLDL and other oxidative stress biomarkers with stable coronary heart disease (CHD). We compared the degree of oxidative stress in patients with CHD and sex-matched healthy control subjects in a case-control study. The study included 64 male subjects: 32 patients with stable CHD and 32 normal control subjects. Levels of circulating oxLDL were measured by a monoclonal antibody 4E6-based competition ELISA. Comparison of oxidative stress marker levels between cases and controls, adjusted for age, revealed significantly higher plasma oxLDL levels (63.32+/-25.49 vs. 37.73+/-20.58 U/l, P=0.001), lower serum levels of autoantibodies against oxLDL (341.53+/-350.46 vs. 796.45+/-1034.2 mU/ml, P=0.021), higher activities of the antioxidant enzymes superoxide dismutase in erythrocytes (951+/-70.2 vs. 771.6+/-191.2 U/g, P=0.032) and glutathione peroxidase in whole blood (GSH-Px: 10714.4+/-3705.4 vs. 5512.2+/-1498.1 U/l, P<0.001). The risk of having CHD was 20.6-fold greater (95% CI, 1.86-228.44, P=0.014) in the highest tertile of the oxLDL distribution than in the lowest, determined by logistic regression analysis on the combined study population after adjustment for age and other potential confounding factors. When the risk associated with GSH-Px levels was calculated, the odds ratio was 305.3 (95% CI, 5.07-18369.95, P=0.006) in the highest tertile compared with the lowest. Our results showed that an oxidative stress occurs in patients with CHD despite being clinically stable and under medical treatment. The combination of oxLDL levels and GSH-Px activity may be useful for the identification of patients with stable CHD.
氧化型低密度脂蛋白(oxLDL)在动脉粥样硬化的发展过程中起着关键作用。本研究的目的是探讨oxLDL及其他氧化应激生物标志物与稳定型冠心病(CHD)之间的关系。在一项病例对照研究中,我们比较了冠心病患者与性别匹配的健康对照者的氧化应激程度。该研究纳入了64名男性受试者:32例稳定型冠心病患者和32名正常对照者。采用基于单克隆抗体4E6的竞争ELISA法测定循环oxLDL水平。经年龄校正后,病例组与对照组氧化应激标志物水平的比较显示,血浆oxLDL水平显著升高(63.32±25.49 vs. 37.73±20.58 U/l,P = 0.001),抗oxLDL自身抗体血清水平降低(341.53±350.46 vs. 796.45±1034.2 mU/ml,P = 0.021),红细胞中超氧化物歧化酶抗氧化酶活性升高(951±70.2 vs. 771.6±191.2 U/g,P = 0.032),全血中谷胱甘肽过氧化物酶(GSH-Px)活性升高(10714.4±3705.4 vs. 5512.2±1498.1 U/l,P<0.001)。经年龄及其他潜在混杂因素校正后,对合并研究人群进行逻辑回归分析,结果显示oxLDL分布最高三分位数组患CHD的风险比最低三分位数组高20.6倍(95%CI,1.86 - 228.44,P = 0.014)。计算与GSH-Px水平相关的风险时,最高三分位数组与最低三分位数组相比,比值比为305.3(95%CI,5.07 - 18369.95,P = 0.006)。我们的结果表明,尽管冠心病患者临床症状稳定且正在接受治疗,但仍存在氧化应激。oxLDL水平与GSH-Px活性的联合检测可能有助于识别稳定型冠心病患者。